Acute hypersensitivity reaction following intravenous ferric carboxymaltose injection for iron deficiency anaemia: a case report

• Authors: Neeraj Kumar , Preeti Bala Gautam , Sarfaraz Ahmad , Danish Qutub , Indira Prasad

Abstracts

EN

Ferric carboxymaltose (FCM) is a non-dextran iron preparation used for intravenous treatment of iron deficiency anaemia (IDA) in adult patients with intolerance or poor response to oral iron therapy. Acute hypersensitivity reactions (HSRs) during iron infusions are very rare but can be life-threatening even after receiving a prior test dose. Here, we report a case of 42 years old female patient who underwent total laparoscopic hysterectomy with bilateral salpingo-oophorectomy. On the next postoperative day she received an injection of ferric carboxy maltose. She was diagnosed with IDA. She presented with the picture of an adverse drug reaction due to injection FCM. She was managed with oxygen, vasopressors, antihistaminics, intravenous fluids and, corticosteroids. She recovered well within 24 hours of intensive care unit admission following this adverse drug reaction. So, careful and precise observation is required in management of adverse reaction following ferric carboxymaltose and prompt recognition and treatment based on severity is warranted.

Keywords

EN

Ferric carboxy maltose; hypersensitivity reaction; intensive care unit

• Publisher: Towarzystwo Pomocy Doraźnej
• Journal: Critical Care Innovations
• Year: 2023
• Volume: 6
• Issue: 1
• Pages: 41-45

Dates

published

2023

Contributors

author

Neeraj Kumar

author

Preeti Bala Gautam

author

Sarfaraz Ahmad

author

Danish Qutub

author

Indira Prasad

References

• Bashiri A, Burstein E, Sheiner E, Mazor M. Anemia during pregnancy and treatment with intravenous iron: review of the literature. Eur J Obstet Gynecol Reprod Biol. 2003; 110(1): 2-7. doi: https://doi.org/10.1016/s0301-2115(03)00113-1
• Freter S, Davidman M, Lipman M, Bercovitch D. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran. Am J Nephrol. 1997; 17(5): 477-479. doi: https://doi.org/10.1159/000169146
• EMA-CHMP 2013. Assessment report for: iron-containing intravenous (IV) medicinal products EMA/549569/2013. [WWW]: http://www.ema.europa.eu/docs/en_GB/document_library/Referralsdocument/IV_iron_31/WC500150771.pdf (accessed 28 December 2022)
• Scott LJ. Ferric carboxymaltose: A review in iron deficiency. Drugs 2018; 78(4): 479–493. doi: https://doi.org/10.1007/s40265-018-0885-7
• WHO. Archived: Iron deficiency anaemia: assessment, prevention and control. [WWW]: https://www.who.int/publications/m/item/iron-children-6to23--archived-iron-deficiency-anaemiaassessment-prevention-and-control (accessed 28 December 2022)

Identifiers

DOI

10.32114/CCI.2023.6.1.41.45

Biblioteka Nauki

29432056